Elissa Bardhi

Elissa Bardhi

Auto-generated profile, based on publicly available information

Elissa Bardhi

Surgical Sciences Division, Department of Surgery, School of Medicine, University of Maryland, Baltimore, Maryland, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2022 in JHEP Reports
Verified
Journal Article
Open access
EBElissa Bardhi
Elissa Bardhi
JMJennifer McDaniels
Jennifer McDaniels
TRThomas Rousselle
Thomas Rousselle
DMDaniel G. Maluf
Daniel G. Maluf
VMVALERIA MAS
VALERIA MAS
Many risk factors and complications impact the success of liver transplantation, such as ischaemia-reperfusion injury, acute rejection, and primary graft dysfunction. Molecular biomarkers have the potential to accurately diagnose, predict, and monitor injury progression or organ failure. There is a critical opportunity for reliable and non-invasive biomarkers to reduce the organ shortage by enabling i) the assessment of donor organ quality, ii) the monitoring of short- and long-term graft function, and iii) the prediction of acute and chronic disease development. To date, no established molecular biomarkers have been used to guide clinical decision-making in transplantation. In this review, we outline the recent advances in cell-free nucleic acid biomarkers for monitoring graft injury in liver transplant recipients. Prior work in this area can be divided into two categories: biomarker discovery and validation studies. Circulating nucleic acids (CNAs) can be found in the extracellular environment pertaining to different biological fluids such as bile, blood, urine, and perfusate. CNAs that are packaged into extracellular vesicles may facilitate intercellular and interorgan communication. Thus, decoding their biological function, cellular origins and molecular composition is imperative for diagnosing causes of graft injury, guiding immunosuppression and improving overall patient survival. Herein, we discuss the most promising molecular biomarkers, their state of development, and the critical aspects of study design in biomarker research for early detection of post-transplant liver injury. Future advances in biomarker studies are expected to personalise post-transplant therapy, leading to improved patient care and outcomes.

22 June 2022 in American Journal of Transplantation
Verified
Journal Article
Open access
KAKellie J. Archer
Kellie J. Archer
EBElissa Bardhi
Elissa Bardhi
DMDaniel G. Maluf
Daniel G. Maluf
JMJennifer McDaniels
Jennifer McDaniels
TRThomas Rousselle
Thomas Rousselle
VMVALERIA MAS
VALERIA MAS
With the development of novel prognostic tools derived from omics technologies, transplant medicine is entering the era of precision medicine. Currently, there are no established predictive biomarkers for posttransplant kidney function. A total of 270 deceased donor pretransplant kidney biopsies were collected and posttransplant function was prospectively monitored. This study first assessed the utility of pretransplant gene expression profiles in predicting 24-month outcomes in a training set (n = 174). Nearly 600 differentially expressed genes were associated with 24-month graft function. Grafts that progressed to low function at 24 months exhibited upregulated immune responses and downregulated metabolic processes at pretransplantation. Using penalized logistic regression modeling, a 55 gene model area under the receiver operating curve (AUROC) for 24-month graft function was 0.994. Gene expression for a subset of candidate genes was then measured in an independent set of pretransplant biopsies (n = 96) using quantitative polymerase chain reaction. The AUROC when using 13 genes with three donor characteristics (age, race, body mass index) was 0.821. Subsequently, a risk score was calculated using this combination for each patient in the validation cohort, demonstrating the translational feasibility of using gene markers as prognostic tools. These findings support the potential of pretransplant transcriptomic biomarkers as novel instruments for improving posttransplant outcome predictions and associated management.

11 May 2021 in Transplantation
Verified
Journal Article
Open access
VMVALERIA MAS
VALERIA MAS
EBElissa Ba Bardhi
Elissa Ba Bardhi
MBMarina Berenguer
Marina Berenguer

29 September 2026 in American Journal of Transplantation
Verified
Journal Article
Open access
VSVrishketan Sethi
Vrishketan Sethi
VGVikraman Gunabushanam
Vikraman Gunabushanam
HLHao Liu
Hao Liu
SPSoumik Purkayastha
Soumik Purkayastha
EBElissa Bardhi
Elissa Bardhi
AHAbhinav Humar
Abhinav Humar